A comprehensive view of Gilead Sciences Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

JPMorgan rates Gilead as overweight, noting its emerging oncology business, and expecting HIV franchise to grow low single-digit CAGR though early 2030s; Biktarvy to remain dominant product with revenues growing from US$10.2B in 2022 to US$12.5B in 2025

Kite Pharma receives FDA approval to start commercial production at its 100,000 square-foot retroviral vector manufacturing facility in Oceanside, California; viral vectors are used to manufacture cell therapies to treat certain blood cancers

Gilead settles patent litigation with generic drug makers Lupin, Apotex, Macleods Pharma, Hetero Labs, and Cipla regarding Gilead’s Descovy, Vemlidy, and Odefsey drugs; generic firms get non-exclusive licenses in US to the drugs beginning in 2031

Gilead’s injectable lenacapavir HIV medication approved by European Commission for use every six months in combination with other antiretrovirals to treat adults with multidrug-resistant HIV; drug will be marketed as Sunlenca in Europe

Moody's: US drug pricing reform in Inflation Reduction Act may have credit-lowering effect on industry; it’s unclear which drugs costs will get negotiated, but potential candidates include drugs from Bristol Myers, Pfizer, Eli Lilly, AbbVie, J&J, Gilead

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count